McKenna Mark C.
SEC insider (Form 3/4/5 filer). CIK 0001749623. Director at TCGX Acquisition Corp. II (TCXB) and 6 other issuers. 12 reported Form 4/5 transactions since Sep 2024; latest on Sep 3, 2026. Located in PALO ALTO, CA.
Companies McKenna Mark C. has filed insider reports for
- TCGX Acquisition Corp. II (TCXB): Director
- Apogee Therapeutics, Inc. (APGE): Director
- Freenome, Inc. (FRNM)
- Spyre Therapeutics, Inc. (SYRE): Director
- Helix Acquisition Corp. III (HLXC): Director
- NewAmsterdam Pharma Co N.V. (NAMS): Director
- BridgeBio Oncology Therapeutics, Inc. (BBOT)
McKenna Mark C.
CIK: 0001749623
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- Sep 3, 2026APGE
Apogee Therapeutics, Inc.
DispositionDirect20K shares- - Jul 20, 2026FRNM
Freenome, Inc.
ConversionDirect30K shares- - Jun 9, 2026APGE
Apogee Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
7.7K shares- - May 27, 2026SYRE
Spyre Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
8K shares- - Jan 7, 2026NAMS
NewAmsterdam Pharma Co N.V.
AwardDirect3.4K shares- - Aug 11, 2025BBOT
BridgeBio Oncology Therapeutics, Inc.
ExerciseDirect30K shares- - Jun 17, 2025APGE
Apogee Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
14.5K shares- - May 29, 2025SYRE
Spyre Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
25K shares- - Jan 7, 2025NAMS
NewAmsterdam Pharma Co N.V.
AwardDirect7K shares- - Jan 6, 2025NAMS
NewAmsterdam Pharma Co N.V.
AwardDirectOption (right to buy)
32.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 3, 2026 |  APGE Apogee Therapeutics, Inc. | Disposition | 20,000 | - | $0 | Direct |
| Jul 20, 2026 |  FRNM Freenome, Inc. | Conversion | 30,000 | - | $0 | Direct |
| Jun 9, 2026 | APGE Apogee Therapeutics, Inc. | Award Stock Option (Right to Buy) | 7,657 | - | - | Direct |
| May 27, 2026 |  SYRE Spyre Therapeutics, Inc. | Award Stock Option (Right to Buy) | 8,026 | - | - | Direct |
| Jan 7, 2026 |  NAMS NewAmsterdam Pharma Co N.V. | Award | 3,400 | - | $0 | Direct |
| Aug 11, 2025 |  BBOT BridgeBio Oncology Therapeutics, Inc. | Exercise | 30,000 | - | - | Direct |
| Jun 17, 2025 | APGE Apogee Therapeutics, Inc. | Award Stock Option (Right to Buy) | 14,461 | - | - | Direct |
| May 29, 2025 | SYRE Spyre Therapeutics, Inc. | Award Stock Option (Right to Buy) | 25,000 | - | - | Direct |
| Jan 7, 2025 | NAMS NewAmsterdam Pharma Co N.V. | Award | 6,960 | - | $0 | Direct |
| Jan 6, 2025 | NAMS NewAmsterdam Pharma Co N.V. | Award Option (right to buy) | 32,500 | - | - | Direct |
1-10 of 12 transactions